- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | CLARITY PHARMACEUTICALS LTD: Cleansing Notice | - | ASX | ||
| Mi | CLARITY PHARMACEUTICALS LTD: Application for quotation of securities - CU6 | 1 | ASX | ||
| 14.05. | CLARITY PHARMACEUTICALS LTD: Clarity receives $9.8 million R&D tax incentive refund | 7 | ASX | ||
| 30.04. | CLARITY PHARMACEUTICALS LTD: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 22.04. | CLARITY PHARMACEUTICALS LTD: Change of Director's Interest Notice - Parker | - | ASX | ||
| 14.04. | Clarity Pharmaceuticals signs manufacturing deal with Nucleus | 1 | Investing.com | ||
| 14.04. | Why Clarity Pharmaceuticals shares just fell 5% on today's announcement | 4 | The Motley Fool Australia | ||
| 13.04. | CLARITY PHARMACEUTICALS LTD: Clarity signs a Commercial Manufacturing Agreement | - | ASX | ||
| CLARITY PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.04. | CLARITY PHARMACEUTICALS LTD: Ceasing to be a substantial holder | - | ASX | ||
| 09.04. | CLARITY PHARMACEUTICALS LTD: Becoming a substantial holder | - | ASX | ||
| 09.04. | CLARITY PHARMACEUTICALS LTD: Final Director's Interest Notice - Biggin | - | ASX | ||
| 08.04. | CLARITY PHARMACEUTICALS LTD: Director Appointment/Resignation | - | ASX | ||
| 07.04. | CLARITY PHARMACEUTICALS LTD: Notification regarding unquoted securities - CU6 | - | ASX | ||
| 31.03. | CLARITY PHARMACEUTICALS LTD: Cleansing Notice | 4 | ASX | ||
| 31.03. | CLARITY PHARMACEUTICALS LTD: Application for quotation of securities - CU6 | 1 | ASX | ||
| 31.03. | CLARITY PHARMACEUTICALS LTD: Co-PSMA data published in the European Urology journal | - | ASX | ||
| 25.03. | CLARITY PHARMACEUTICALS LTD: Becoming a substantial holder | - | ASX | ||
| 25.03. | Clarity Pharmaceuticals schließt Liefervereinbarung für Kupfer-64 mit Theragenics | 2 | Investing.com Deutsch | ||
| 25.03. | Clarity Pharmaceuticals signs copper-64 supply deal with Theragenics | 2 | Investing.com | ||
| 25.03. | Clarity Pharma Secures Key Supply Deal to Boost Commercialisation of Prostate Cancer Agent | 2 | smallcaps.com.au |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 128,45 | +1,62 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert | ||
| BAYER | 38,820 | -0,23 % | Bayer meldet überzeugende Darolutamid-Daten der Phase-II-Studie ARASEC | DJ Bayer meldet überzeugende Darolutamid-Daten der Phase-II-Studie ARASEC
DOW JONES--Bayer hat auf der Jahrestagung der American Urological Association (AUA) 2026 neue Daten der Phase-II-Studie... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 83,24 | 0,00 % | Bright Minds Biosciences GAAP EPS of -$1.09 for three months ended March 31 | ||
| ETON PHARMACEUTICALS | 34,990 | -0,03 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,980 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 0,513 | -0,64 % | Sunshine Biopharma Inc.: Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin | FORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,230 | 0,00 % | Citizens reiterates Aquestive stock rating on Anaphylm progress | ||
| NOVO NORDISK | 37,935 | -0,28 % | Novo Nordisk: Erste Früchte der Investitionsoffensive - trägt die Story trotz Wachstumsrally noch weiter? | Novo Nordisk hat im ersten Quartal 2024 eindrucksvoll unter Beweis gestellt, dass die massiven Investitionen in Produktionskapazitäten beginnen, sich auszuzahlen. Trotz hoher Bewertungskennzahlen sehen... ► Artikel lesen | |
| GSK | 22,200 | +0,27 % | GSK: Japan's MHLW Expands Eligible Population For Arexvy | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for RSV vaccine, Arexvy, to include... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 17,240 | +0,29 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| ELI LILLY | 898,10 | +0,12 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| JUPITER NEUROSCIENCES | 0,270 | -0,22 % | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,150 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform | SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with... ► Artikel lesen | |
| LB PHARMACEUTICALS | 27,980 | -0,07 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen | |
| PFIZER | 22,335 | 0,00 % | Unterbewertet - Analysten rücken LifeScience in den Fokus! Bayer, Vidac Pharma, Novo Nordisk und Pfizer im Check | Dass Analysten den LifeScience-Bereich zuletzt wieder besser einschätzen, zeigt die dynamische Kursziel-Anpassung der DZ Bank für Bayer. Der starke Jahresstart des Pharma- und Agrarchemiekonzerns führt... ► Artikel lesen |
CLARITY PHARMACEUTICALS LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 1,520 Euro und damit -7,88 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLARITY PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.